Robby Wu, DO
Cardiovascular Disease · Tampa, FLNPI 1659614451
Payments from drug & device makers
Across 430 payments — averaging $1112.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procyrion, Inc.$263K
- E.r. Squibb & Sons, L.L.C.$166K
- Lexicon Pharmaceuticals, Inc.$26K
- Abbott$13K
- Biotronik Inc.$2K
- Abiomed$2K
- plus $6K from 24 others
Across 3 payments — averaging $580.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Lexicon Pharmaceuticals, Inc.$2K
What the payments were for
- Consulting fees$14,2658%
- Speaking & faculty fees$141,44174%
- Travel & lodging$15,2388%
- Food & beverage$18,87010%
- Education$2480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procyrion, Inc. | 9 | $263,105 |
| E.r. Squibb & Sons, L.L.C. | 131 | $166,059 |
| Lexicon Pharmaceuticals, Inc. | 7 | $25,664 |
| Abbott | 185 | $13,194 |
| Biotronik Inc. | 4 | $2,308 |
| Abiomed | 18 | $2,194 |
| Medtronic | 5 | $1,205 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $778 |
| AstraZeneca | 9 | $720 |
| Cvrx, Inc. | 6 | $490 |
| Ancora Heart, Inc. | 4 | $416 |
| Endotronix, Inc. | 2 | $244 |
| Johnson & Johnson | 8 | $209 |
| Astellas Pharma US Inc | 2 | $198 |
| Edwards Lifesciences | 2 | $180 |
| Itamar Medical Inc | 1 | $146 |
| Alnylam Pharmaceuticals Inc. | 2 | $129 |
| Daxor Corporation | 1 | $128 |
| Amgen | 1 | $122 |
| Bayer | 1 | $122 |
| Actelion Pharmaceuticals US, Inc. | 1 | $121 |
| Bridgebio Pharma, Inc. | 1 | $120 |
| Mallinckrodt Hospital Products Inc. | 1 | $94 |
| Pfizer | 4 | $77 |
| Merck | 1 | $63 |
| Boehringer Ingelheim | 3 | $42 |
| Biosense Webster, Inc. | 1 | $31 |
| One Lambda, Inc. | 1 | $24 |
| Impulse Dynamics (USA) Inc. | 1 | $14 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$156,601
- CARDIOMEMS$5,379
- Impella$1,880
- HeartMate PHP$1,090
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$730
- CardioMEMS HF System$683
- AORTIX SYSTEM$508
- Barostim Neo System$451
- FARXIGA$364
- MitraClip System$299
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$244
- AccuCinch$218
- Ensite Cardiac Mapping System$170
- TactiCath Quartz CFA Catheter$166
- AMPLATZER Occluders$157
- Assurity Pacemaker$152
- Edwards SAPIEN 3 Transcatheter Heart Valve$150
- WatchPATONE$146
- Connect HF$144
- BRILINTA$134
How this compares
$478,210 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CamzyosMavacamten | 166 | $1,352,468 |
| VyndamaxTafamidis | 18 | $840,270 |
| FarxigaDapagliflozin Propanediol | 179 | $204,531 |
| EntrestoSacubitril/Valsartan | 140 | $189,713 |
| EliquisApixaban | 61 | $78,132 |
| JardianceEmpagliflozin | 35 | $49,414 |
| OzempicSemaglutide | 31 | $34,418 |
| XareltoRivaroxaban | 19 | $28,597 |
| CorlanorIvabradine Hcl | 21 | $19,730 |
| Repatha SureclickEvolocumab | 17 | $14,710 |
| Metoprolol Succinate | 159 | $2,657 |
| Eplerenone | 16 | $2,057 |
| Ezetimibe | 60 | $1,774 |
| Dofetilide | 14 | $1,591 |
| Rosuvastatin Calcium | 77 | $1,402 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Camzyos | $166,059 | $1,352,468166 claims |
| PfizerVyndamax, Eliquis | $77 | $918,40279 claims |
| AstraZenecaFarxiga | $720 | $204,531179 claims |
| NovartisEntresto | $13 | $189,713140 claims |
| Boehringer IngelheimJardiance | $42 | $49,41435 claims |
| Johnson & JohnsonXarelto | $209 | $28,59719 claims |
| AmgenCorlanor | $122 | $19,73021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Tampa
- Hiram BezerraTampa$1.6M
- Arthur LabovitzTampa$689K
- Michael KorenGainesville$31M
- Seth BaumBoca Raton$11.1M
- Alexis GutierrezHialeah$8M
- Eric SpivackAventura$7.1M
- William OneillNaples$4.6M
- Rafik AbadierInverness$4.4M
- Alvaro MurciaPembroke Pines$4M
- David HotchkissPort Charlotte$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.